High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 47, 2016, Pages 13432-13437

  Yoshikawa, Yoshie ^a   Emi, Mitsuru ^a,b   Hashimoto Tamaoki, Tomoko ^a   Ohmuraya, Masaki ^a   Sato, Ayuko ^a   Tsujimura, Tohru ^a   Hasegawa, Seiki ^a   Nakano, Takashi ^a   Nasu, Masaki ^b   Pastorino, Sandra ^b   Szymiczek, Agata ^b   Bononi, Angela ^b   Tanji, Mika ^b   Pagano, Ian ^b   Gaudino, Giovanni ^b   Napolitano, Andrea ^b   Goparaju, Chandra ^c   Pass, Harvey I ^c   Yang, Haining ^b   Carbone, Michele ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BAP1; Mesothelioma; PBRM1; SETD2; SMARCC1

Indexed keywords

BRCA1 ASSOCIATED PROTEIN 1; BRCA1 PROTEIN; GENOMIC DNA; PROTEIN; SET DOMAIN CONTAINING PROTEIN 2; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG; MESSENGER RNA;

BAP1 GENE; CHROMOSOME 13P; CHROMOSOME 13P21; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; GENE; GENE CLUSTER; GENE DELETION; GENE DOSAGE; GENE INACTIVATION; GENE LOSS; GENE REARRANGEMENT; GENOME; HUMAN; MESOTHELIOMA; MICROARRAY ANALYSIS; NEXT GENERATION SEQUENCING; PBRM1 GENE; POINT MUTATION; PRIORITY JOURNAL; SETD2 GENE; SMARCC1 GENE; SOMATIC MUTATION; ALLELE; CHROMOSOME 3; COPY NUMBER VARIATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; LUNG TUMOR; METABOLISM; MULTIGENE FAMILY; MUTATION; REPRODUCIBILITY; TUMOR CELL LINE;

ALLELES; CELL LINE, TUMOR; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 3; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MULTIGENE FAMILY; MUTATION; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 84996671366     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1612074113     Document Type: Article

References (48)

1. Carbone M, et al. (2016) Consensus report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 11(8):1246-62.
2. Carbone M, et al. (2015) Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s. PLoS Genet 11(12):e1005633.
3. Gazdar AF, Carbone M (2003) Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 5(3):177-181.
4. Carbone M, Rizzo P, Pass H (2000) Simian virus 40: The link with human malignant mesothelioma is well established. Anticancer Res 20(2 A):875-877.
5. Ostroff RM, et al. (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 7(10):e46091.
6. Napolitano A, et al. (2016) HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res 22(12):3087-3096.
7. Napolitano A, Carbone M (2016) Malignant mesothelioma: Time to translate? Trends in Cancer 2(9):467-474.
8. Gray PN, Dunlop CL, Elliott AM (2015) Not all next generation sequencing diagnostics are created equal: Understanding the nuances of solid tumor assay design for somatic mutation detection. Cancers (Basel) 7(3):1313-1332.
9. Guo G, et al. (2015) Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 75(2):264-269.
10. Lo Iacono M, et al. (2015) Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol 10(3):492-499.
11. Bueno R, et al. (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48(4):407-416.
12. Ugurluer G, et al. (2016) Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma. Anticancer Res 36(5):2331-2338.
13. Bott M, et al. (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43(7):668-672.
14. Testa JR, et al. (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022-1025.
15. Zauderer MG, et al. (2013) Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol 8(11):1430-1433.
16. Carbone M, Gaudino G, Yang H (2015) Recent insights emerging from malignant mesothelioma genome sequencing. J Thorac Oncol 10(3):409-411.
17. Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153(1):17-37.
18. Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand MC (2012) Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 136(3):277-293.
19. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR (1993) Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53(18):4349-4355.
20. Yoshikawa Y, et al. (2012) Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 103(5):868-874.
21. Nasu M, et al. (2015) High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10(4):565-576.
22. Zeiger MA, Gnarra JR, Zbar B, Linehan WM, Pass HI (1994) Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes Cancer 11(1):15-20.
23. Lindholm PM, et al. (2007) Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 119(1-2):46-52.
24. Taniguchi T, et al. (2007) Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98(3):438-446.
25. Ivanov SV, et al. (2009) Genomic events associated with progression of pleural malignant mesothelioma. Int J cancer 124(3):589-599.
26. Yoshikawa Y, et al. (2011) Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 39(6):1365-1374.
27. Hesson LB, Cooper WN, Latif F (2007) Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26(52):7283-7301.
28. Tubio JM, Estivill X (2011) Cancer: When catastrophe strikes a cell. Nature 470(7335):476-477.
29. Yoshikawa Y, et al. (2015) Biallelic germline and somatic mutations in malignant mesothelioma: Multiple mutations in transcription regulators including mSWI/SNF genes. Int J Cancer 136(3):560-571.
30. Dalgliesh GL, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279):360-363.
31. Varela I, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331):539-542.
32. Patil V, Pal J, Somasundaram K (2015) Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget 6(41):43452-43471.
33. Tan J, et al. (2015) Genomic landscapes of breast fibroepithelial tumors. Nat Genet 47(11):1341-1345.
34. Lee JJ, et al. (2015) Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. Clin Epigenetics 7:59.
35. Li J, et al. (May 14, 2016) SETD2: An epigenetic modifier with tumor suppressor functionality. Oncotarget, 10.18632/oncotarget.9368.
36. Parker H, et al. (June 10, 2016) Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia.
37. Huang KK, et al. (September 3, 2015) SETD2 histone modifier loss in aggressive GI stromal tumours. Gut, 10.1136/gutjnl-2015-309482.
38. Jiao Y, et al. (2013) Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45(12):1470-1473.
39. Wang X, Roberts CW (2014) CARMA: CARM1 methylation of SWI/SNF in breast cancer. Cancer Cell 25(1):3-4.
40. Mo D, et al. (2015) Low PBRM1 identifies tumor progression and poor prognosis in breast cancer. Int J Clin Exp Pathol 8(8):9307-9313.
41. Del Bove J, et al. (2011) Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene. Epigenetics 6(12):1444-1453.
42. Napolitano A, et al. (2016) Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35(15):1996-2002.
43. Wang SS, et al. (2014) Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci USA 111(46):16538-16543.
44. Lek M, et al.; Exome Aggregation Consortium (2016) Analysis of protein-coding genetic variation in 60, 706 humans. Nature 536(7616):285-291.
45. Carbone M, et al. (2012) Malignant mesothelioma: Facts, myths, and hypotheses. J Cell Physiol 227(1):44-58.
46. Carbone M, et al. (2013) BAP1 and cancer. Nat Rev Cancer 13(3):153-159.
47. Brownlee PM, Chambers AL, Cloney R, Bianchi A, Downs JA (2014) BAF180 promotes cohesion and prevents genome instability and aneuploidy. Cell Reports 6(6):973-981.
48. Hellmann F, Verdi M, Schlemper BR, Jr, Caponi S (2014) 50th anniversary of the Declaration of Helsinki: The double standard was introduced. Arch Med Res 45(7):600-601.